Wegovy is FDA-approved for chronic weight management in combination with diet and exercise for: Adults with obesity (with a BMI of 30 or higher) Adults who are overweight (with a BMI of 27 or higher) with at least one weight-related condition such as heart disease, high blood pressure, sleep apnea, or type 2 diabetes, Adolescents 12 years of age and older with an initial BMI at or above the 95th percentile for age and sex Wegovy is also FDA-approved for reducing the risk of serious cardiovascular problems like heart attack in adults with obesity or overweight
(D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions
Research is still needed to confirm the safety and efficacy of microdosing tirzepatide
For a 50mg vial of 5-Amino-1MQ with a target dose of 5mg per injection: 50mg 5mg = 10 doses 10 doses 0.25mL = 2.5mL bacteriostatic water This creates a 20mg/mL solution
Chi KH, Chiou TJ, Li CP, Chen SY, Chao Y
GLP-1 injections like semaglutide and tirzepatide are powerful tools, but the real difference lies in how theyre managed